AFYAConsumer Defensive · Education & Training ServicesThe 9 Wall Street analysts covering Afya Ltd. hold a median 12-month price target of $17 — +22.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 23 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Afya Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (89): Sales and profits are climbing, and climbing faster than before.
Momentum (42): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AFYA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +22.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 June 2026 | JP Morgan | Maintains | Neutral | $22 → $21 |
| 30 Apr 2026 | JP Morgan | Maintains | Neutral | — |
| 24 Feb 2026 | B of A Securities | Downgrade | Neutral | — |
| 13 Feb 2026 | Morgan Stanley | Downgrade | Underweight | — |
| 16 Jan 2026 | UBS | Downgrade | Neutral | — |
| 8 Jan 2026 | UBS | Maintains | Buy | — |
| 7 Jan 2026 | JP Morgan | Downgrade | Neutral | — |
| 8 Sept 2025 | JP Morgan | Upgrade | Overweight | — |
| 8 Sept 2025 | UBS | Upgrade | Buy | — |
| 29 July 2025 | Citigroup | Upgrade | Neutral | — |
| 12 June 2025 | UBS | Maintains | Neutral | — |
| 11 Mar 2025 | Morgan Stanley | Downgrade | Underweight | — |
| 31 Jan 2025 | Citigroup | Downgrade | Sell | — |
| 17 Jan 2025 | JP Morgan | Maintains | Neutral | — |
| 3 Dec 2024 | Goldman Sachs | Initiates | Sell | — |
| 30 Aug 2024 | UBS | Initiates | Neutral | — |
| 21 June 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 22 Jan 2024 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 27 Nov 2023 | JP Morgan | Downgrade | Neutral | — |
| 13 Oct 2023 | Morgan Stanley | Upgrade | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AFYA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Sept 2026, Afya Ltd. returned −12.0% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 61% of US stocks
Cheaper than 88% of US stocks
Cheaper than 65% of US stocks
Cheaper than 56% of US stocks
Higher than 41% of US stocks
Higher than 52% of US stocks
Higher than 75% of US stocks
Higher than 87% of US stocks
Higher than 83% of US stocks
Higher than 77% of US stocks
Higher than 89% of US stocks
Higher than 94% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Afya Ltd. has a market value of $1.2B and an enterprise value of $650.4M.
Revenue in the twelve months to 30 June 2026: $3.8B. The latest quarter grew 5.7% year on year.
Net income over the same four quarters: $797.9M, a 20.9% net margin.
Free cash flow in the twelve months to 30 June 2026: $1.3B.
Afya Ltd. spent $0.0 on dividends in the twelve months to 30 June 2026.
Trailing P/E: 8.0×; forward P/E: 6.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 19.48%, paying out 40% of earnings.
Afya Ltd. employs 9,395 people — $407K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Afya Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Afya Limited's merger and acquisition conference call. The transcript covers the company's M&A-related discussions with investors and analysts.
Why it matters — The transcript offers AFYA watchers insight into the company's M&A strategy and the management's commentary on related activities.
Afya Ltd. (AFYA) was added to the Zacks Rank #5 (Strong Sell) List on September 24th, 2026, alongside AGCO and AGBK. The company's stock has been assigned a Strong Sell rating by Zacks Investment Research.
Why it matters — This rating change signals that Zacks' quantitative model has downgraded its outlook on AFYA, which AFYA watchers would care about as a bearish analyst signal.
Afya Limited announced it has entered into a binding merger agreement with Yduqs Participações S.A. to combine the two Brazilian higher education platforms in a proposed business combination. The transaction would bring together Afya's medical education operations with Yduqs' higher education business.
Why it matters — This merger agreement represents a major strategic development that could significantly reshape Afya's business structure and position within Brazil's higher education sector.
Afya Limited announced that Brazil's Ministry of Education has authorized an increase of 17 medical seats at its ITPAC Cruzeiro do Sul institution (AFYA Cruzeiro do Sul).
Why it matters — The authorized seat increase expands capacity at one of Afya's medical education institutions, a key growth area for the company.
Zacks Investment Research added AFYA, along with AGBK and APTV, to its Zacks Rank #5 (Strong Sell) List on September 18th, 2026.
Why it matters — AFYA watchers would care because the stock has been assigned the lowest Zacks ranking, indicating a "Strong Sell" rating from the research firm.
The 9 Wall Street analysts covering Afya Ltd. have a median 12-month price target of $17, with estimates ranging from $15 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Afya Ltd., 1 rate it a Buy, 5 a Hold and 3 a Sell. Ticker Nerd's systematic factor model ranks Afya Ltd. 84 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 23 Sept 2026, Afya Ltd. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (89 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +22.6% from the last close, and Ticker Nerd's factor model ranks Afya Ltd. 84 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Afya Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AFYA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $21 over the next 12 months.
Afya Ltd. returned -12.0% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Afya Ltd Class A Common Shares represent equity in Afya Ltd, a Brazil-based medical education and healthcare practice solutions company. Afya focuses on an integrated physician-centered platform that supports students and doctors through undergraduate medical education, residency preparation, continuing education, postgraduate programs, and digital practice-management tools.
The most recent item we track (Seeking Alpha, 24 Sept 2026): "Afya Limited (AFYA) M&A Call Transcript". Seeking Alpha published a transcript of Afya Limited's merger and acquisition conference call. The transcript covers the company's M&A-related discussions with investors and analysts.
Afya Ltd Class A Common Shares represent equity in Afya Ltd, a Brazil-based medical education and healthcare practice solutions company. Afya focuses on an integrated physician-centered platform that supports students and doctors through undergraduate medical education, residency preparation, continuing education, postgraduate programs, and digital practice-management tools. Its business is organized around education services, digital content, residency preparatory and specialization programs, and medical practice solutions, giving it a broad role across the medical training lifecycle. The company serves medical students, practicing physicians, and healthcare professionals seeking educational content and professional support tools. Afya’s Class A common shares are one class of its publicly traded equity and carry standard voting and ownership rights within the company’s share structure.
9,395 employees · Brazil · https://www.afya.com.br
